| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | HIV Modelling Consortium Treatment as Prevention Editorial Writing Group | |
| P2860 | cites work | Tenofovir-based pre-exposure prophylaxis for HIV prevention | Q22242692 |
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women | Q24629582 | ||
| Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 | ||
| HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention | Q26853353 | ||
| Breakthrough of the year. HIV treatment as prevention | Q28256009 | ||
| Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis | Q28476684 | ||
| Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model | Q29305377 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Economic returns to investment in AIDS treatment in low and middle income countries | Q31036894 | ||
| Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review | Q33979497 | ||
| Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis | Q34067511 | ||
| Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa | Q34090912 | ||
| Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland | Q34113515 | ||
| Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study | Q34126545 | ||
| Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. | Q34166980 | ||
| HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? | Q34339450 | ||
| HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation | Q34339458 | ||
| HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa | Q34339465 | ||
| HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions | Q34339471 | ||
| HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes | Q34339517 | ||
| HIV treatment as prevention: the utility and limitations of ecological observation | Q34339533 | ||
| HIV treatment as prevention: issues in economic evaluation | Q34339555 | ||
| HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention | Q34341297 | ||
| Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study | Q35166201 | ||
| The cost of providing comprehensive HIV treatment in PEPFAR-supported programs | Q35576296 | ||
| HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy | Q35680189 | ||
| Antiretroviral therapy refusal among newly diagnosed HIV-infected adults | Q35737611 | ||
| The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study | Q35742086 | ||
| Concurrent partnerships, acute infection and HIV epidemic dynamics among young adults in Zimbabwe | Q36089056 | ||
| Concurrent sexual partnerships and primary HIV infection: a critical interaction | Q36460667 | ||
| Antiretroviral therapy in prevention of HIV and TB: update on current research efforts | Q36493044 | ||
| Antiviral agents and HIV prevention: controversies, conflicts, and consensus | Q36836680 | ||
| Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies | Q36941573 | ||
| Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries | Q37108925 | ||
| Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis | Q37112617 | ||
| Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis | Q37452644 | ||
| HIV-1 transmission, by stage of infection | Q38875941 | ||
| Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy | Q38876857 | ||
| Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes | Q38889802 | ||
| Confidential HIV testing and condom promotion in Africa. Impact on HIV and gonorrhea rates | Q39232951 | ||
| Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings | Q39353947 | ||
| Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania | Q39501645 | ||
| Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines | Q39707218 | ||
| Towards an improved investment approach for an effective response to HIV/AIDS. | Q44667685 | ||
| No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa | Q44773899 | ||
| Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model | Q46623836 | ||
| Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis | Q73615039 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | public domain | Q19652 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | decision making | Q1331926 |
| prevention | Q1717246 | ||
| prevention of HIV/AIDS | Q7242372 | ||
| human immunodeficiency virus infectious disease | Q18556697 | ||
| Retroviridae infectious disease | Q19000689 | ||
| biomedical investigative technique | Q66648976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e1001259 | |
| P577 | publication date | 2012-07-10 | |
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making | |
| P478 | volume | 9 |
| Q34180729 | ARV-based HIV prevention for women - where we are in 2014. |
| Q37635041 | Antiretroviral therapy for the prevention of HIV transmission: what will it take? |
| Q34379806 | Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? |
| Q38165803 | Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US. |
| Q30994543 | Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era. |
| Q28602867 | CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study |
| Q37404649 | Can a pill prevent HIV? Negotiating the biomedicalisation of HIV prevention. |
| Q24630559 | Combination prevention: new hope for stopping the epidemic |
| Q47191055 | Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa |
| Q36205807 | Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China |
| Q36175183 | Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study |
| Q35067151 | Early HIV infection in the United States: a virus's eye view |
| Q37443074 | Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Côte d'Ivoire |
| Q38407675 | Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements |
| Q35891055 | Estimating mother-to-child HIV transmission rates in Cameroon in 2011: a computer simulation approach |
| Q37433470 | Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study |
| Q55546871 | Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a |
| Q33703135 | Global HIV epidemiology: A guide for strategies in prevention and care. |
| Q36212240 | HCV prevalence can predict HIV epidemic potential among people who inject drugs: mathematical modeling analysis |
| Q28080917 | HIV treatment as prevention: contradictory perspectives from dynamic mathematical models |
| Q34339458 | HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation |
| Q34339465 | HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa |
| Q35164742 | HIV treatment-as-prevention research: authors' reply |
| Q37483779 | HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model |
| Q42239869 | Health care practices and associated service needs in a sample of HIV-positive incarcerated men in Puerto Rico: implications for retention in care |
| Q39238761 | Hepatitis C treatment as prevention: evidence, feasibility, and challenges |
| Q37489326 | Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries |
| Q36091605 | Impact of Heterogeneity in Sexual Behavior on Effectiveness in Reducing HIV Transmission with Test-and-Treat Strategy |
| Q34629173 | Individualized diagnosis interventions can add significant effectiveness in reducing human immunodeficiency virus incidence among men who have sex with men: insights from Southern California |
| Q24277713 | Modeling infectious disease dynamics in the complex landscape of global health |
| Q34077702 | Modeling scenarios for the end of AIDS |
| Q36888158 | Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk |
| Q35049714 | Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations |
| Q36812534 | Overview of the current state of the epidemic |
| Q28081560 | Pharmaceutical HIV prevention technologies in the UK: six domains for social science research |
| Q37608040 | Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS. |
| Q37203836 | Prospects of elimination of HIV with test-and-treat strategy |
| Q34971438 | Sexual healthcare preferences among gay and bisexual men: a qualitative study in San Francisco, California |
| Q44467564 | Test and treat all as soon as possible |
| Q38245023 | The HIV care cascade and antiretroviral therapy in female sex workers: implications for HIV prevention |
| Q47553576 | Using Contact Patterns to Inform HIV Interventions in Persons Who Inject Drugs in Northern Vietnam |
| Q34526461 | Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence |
| Q46553256 | Women and ARV-based prevention: opportunities and challenges |
Search more.